Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biosimilar Uptake: The Importance of Healthcare Provider Education
Sonia Oskouei, Andrew R. Kusmierczyk
Pharmaceutical Medicine (2021) Vol. 35, Iss. 4, pp. 215-224
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Bridging the gap: The future of biosimilars regulations
Anan S. Jarab, Shrouq Abu Heshmeh, Ahmad Z. Al Meslamani
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 4
Efforts of the Pharmaceuticals and Medical Devices Agency of Japanese regulatory agency in supporting biosimilar development and disseminate information
Ryosuke Kuribayashi, Aya Hariu, Yuka Saino, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome
Jun Ho Jang, Bing Han, Jinah Jung, et al.
BioDrugs (2025)
Open Access
Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease
Gionata Fiorino, Ashwin N. Ananthakrishnan, Russell D. Cohen, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1561-1561
Open Access
Facilitators and barriers to generic and biosimilar medications in the Middle East and North Africa: insights from physicians and pharmacists—a systematic review
Kefah Ali Alqawasmeh, Thomas Mason, Abigail Morris, et al.
European Journal of Clinical Pharmacology (2025)
Open Access
ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology
Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, et al.
JCO Oncology Practice (2023) Vol. 19, Iss. 7, pp. 411-419
Open Access | Times Cited: 10
Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective
Kerise Clarke, M. Ainslie-Garcia, Nicole Ferko, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 952-962
Open Access | Times Cited: 3
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans
Tianzhou Yu, Shihan Jin, Chang Li, et al.
BioDrugs (2023) Vol. 37, Iss. 4, pp. 531-540
Open Access | Times Cited: 8
Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study
Gyeongseon Shin, Byung Soo Kim, Do Yeun Kim, et al.
BioDrugs (2024) Vol. 38, Iss. 2, pp. 301-311
Open Access | Times Cited: 2
Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy
Carly Giavatto, Jessica Mourani, Casey A. Fitzpatrick, et al.
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 2, pp. 175-182
Open Access | Times Cited: 2
Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
Tomás Gabriel Bas, Vannessa Duarte
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 925-925
Open Access | Times Cited: 2
Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars
Chiara Gasteiger, Keith J. Petrie
Research in Social and Administrative Pharmacy (2022) Vol. 18, Iss. 10, pp. 3860-3863
Closed Access | Times Cited: 11
A review of biosimilars for rheumatoid arthritis
Carly Conran, Larry W. Moreland
Current Opinion in Pharmacology (2022) Vol. 64, pp. 102234-102234
Closed Access | Times Cited: 11
Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey
Yang Hu, Zaiwei Song, Dan Jiang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
Pharmacists’ Perspectives of Biosimilars: A Systematic Review
Noraisyah Mohd Sani, Zoriah Aziz, Rema Panickar, et al.
BioDrugs (2022) Vol. 36, Iss. 4, pp. 489-508
Closed Access | Times Cited: 9
A bio-what? Medical companions’ perceptions towards biosimilars and information needs in rheumatology
Chiara Gasteiger, Urte Scholz, Keith J. Petrie, et al.
Rheumatology International (2021) Vol. 42, Iss. 11, pp. 1993-2002
Closed Access | Times Cited: 9
Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines
Yannick Vandenplas, Steven Simoens, Florian Turk, et al.
Applied Health Economics and Health Policy (2022) Vol. 20, Iss. 6, pp. 803-817
Open Access | Times Cited: 3
Malaysian Hospital Pharmacists’ Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey
Noraisyah Mohd Sani, Zoriah Aziz, Adeeba Kamarulzaman
BioDrugs (2022) Vol. 37, Iss. 1, pp. 109-120
Open Access | Times Cited: 3
Provider perceptions of barriers to biosimilar utilization in community oncology practices
Owanate Briggs, Carolyn M. Brown, Puneeth Indurlal, et al.
Journal of the American Pharmacists Association (2024) Vol. 64, Iss. 4, pp. 102082-102082
Closed Access
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review
G. Fox, Mark Bernauer, Jennifer Stephens, et al.
ClinicoEconomics and Outcomes Research (2024) Vol. Volume 16, pp. 247-416
Open Access
Conocimiento de la terapia biológica en pacientes con enfermedades inmunomediadas. Estudio BIOINFO
Carlos Seguí-Solanes, Lidia Estrada, Esther Ramírez Herráiz, et al.
Farmacia Hospitalaria (2024)
Open Access
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease
Gary R. Lichtenstein, Arif Soonasra, Mark Latymer, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 7, pp. 691-708
Open Access
Acceptability of CYLTEZO pen among biologics autoinjector patients, autoinjector Naïve patients, and healthcare professionals
Raúl Castro Pérez, Julie D. Suman, Joe Reynolds
Expert Opinion on Drug Delivery (2024) Vol. 21, Iss. 12, pp. 1879-1888
Closed Access
[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study
Carlos Seguí-Solanes, Lidia Estrada, Esther Ramírez Herráiz, et al.
Farmacia Hospitalaria (2024)
Open Access
Regulatory Framework for Supporting the Integration and Use of Biosimilars in the Private Healthcare System of the United Arab Emirates (UAE)
Mohamed Farghaly, Kareem Ahmed El-Fass, Neha Amin, et al.
Cureus (2024)
Open Access
Page 1 - Next Page

Scroll to top